Paratek Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
PRTK Paratek Pharmaceuticals Inc
EGRAY Energy Resources Of Australia Ltd
IVAC Intevac Inc
AMPX Amprius Technologies Inc
PFE Pfizer Inc
BNOX Bionomics Ltd
CRKN Crown Electrokinetics Corp.
CAE CAE Inc
YMAB Y-mAbs Therapeutics Inc
VINE Fresh Vine Wine Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

Closing Price: $2.54

Day's Change: 0.42 (19.81%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.80

Day's Low: 2.38

Volume (Heavy Day) Volume: 5,822,350 10-day average volume: 1,778,407: 5,822,350

Unable to locate that news article. Back to news results

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and